Stock In Focus – TAM Stock Screener – Innoviva Inc (NASDAQ: INVA)

As part of our ongoing series here at The Acquirer’s Multiple, we provide this feature article titled ‘Stock in Focus‘ where we focus on one of the stocks from our Stock Screeners.

One of the cheapest stocks in our Stock Screeners is Innoviva Inc (NASDAQ: INVA).

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance’s respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. The firm collaborates with and receives funding from GlaxoSmithKline.

A quick look at Innoviva Inc’s share price history (below) over the past twelve months shows that the price is up 4%. Here’s why the company is undervalued.

Summary

Market Cap: $1.09 Billion

Enterprise Value: $1.09 Billion

Operating Earnings*

Operating Earnings: $286 Million

Acquirer’s Multiple

Acquirer’s Multiple: 3.81

Free Cash Flow (TTM)

Free Cash Flow: $277 Million

FCF/EV Yield:

FCF/EV Yield: 25%

Other Indicators

Piotroski F-Score: 5

Altman Z-Score: 2.79

Beneish M-Score: -2.85